2020 drug approvals rise despite Covid-19
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
The pandemic releases its grip on clinical trials
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Novartis turns to Beigene for a PD-1 blocker
The pharma giant resorts to deal-making for a much-needed late-stage IO asset, leaving its own PD-1 agent out in the cold.
Astrazeneca shows megamergers were still possible in 2020
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Hope versus experience in glioblastoma
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
